US 12,186,350 B2
Antitumor effect potentiator
Kenji Kangawa, Suita (JP); Takashi Nojiri, Suita (JP); Motofumi Kumazoe, Suita (JP); Yasutake Tanaka, Suita (JP); Yoshiyuki Shishido, Minato-ku (JP); Takashi Asahara, Minato-ku (JP); Takahito Miura, Minato-ku (JP); and Keisuke Taniguchi, Minato-ku (JP)
Assigned to NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER, Suita (JP); and KABUSHIKI KAISHA YAKULT HONSHA, Minato-ku (JP)
Appl. No. 17/279,322
Filed by NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER, Suita (JP); and KABUSHIKI KAISHA YAKULT HONSHA, Minato-ku (JP)
PCT Filed Sep. 25, 2019, PCT No. PCT/JP2019/037623
§ 371(c)(1), (2) Date Mar. 24, 2021,
PCT Pub. No. WO2020/067170, PCT Pub. Date Apr. 2, 2020.
Claims priority of application No. 2018-178746 (JP), filed on Sep. 25, 2018.
Prior Publication US 2022/0000949 A1, Jan. 6, 2022
Int. Cl. A61K 35/747 (2015.01); A61K 31/702 (2006.01); A61K 35/00 (2006.01); A61K 35/745 (2015.01); A61P 35/00 (2006.01); C07K 16/28 (2006.01)
CPC A61K 35/747 (2013.01) [A61K 31/702 (2013.01); A61K 35/745 (2013.01); A61P 35/00 (2018.01); C07K 16/2818 (2013.01); C07K 16/2827 (2013.01); A61K 2035/115 (2013.01)] 2 Claims
OG exemplary drawing
 
1. A method for potentiating an antitumor effect of an immune checkpoint inhibitor, the method comprising:
administering an effective amount of a probiotic, a prebiotic, and an immune checkpoint inhibitor to a subject in need thereof,
wherein the probiotic comprises Lactobacillus casei YIT9029 (FERM BP-1366) and Bifidobacterium breve YIT12272 (FERM BP-11320),
the prebiotic is a galactooligosaccharide, and
the immune checkpoint inhibitor is an anti-PD-1 antibody.